Recently, emerging immunotherapies such as programmed cell death 1 (PD-1) inhibitors have shown excellent efficacy in the treatment of drug-resistant and recurrent GTN (4). This evidence concerns the gene PDCD1 and gestational trophoblastic neoplasm.